Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 21, 2026.

Oxidative Stress in Schizophrenia

Iztok Grabnar, Tomas Vovk, Blanka Kores Plesnicar and 1 more

Current Neuropharmacology · 2011

doi:10.2174/157015911795596595

Abstract

Increasing evidence indicates that oxidative damage exists in schizophrenia. Available literature about possible mechanisms of oxidative stress induction was reviewed. Furthermore, possibilities of measuring biomarkers of schizophrenia outside the central nervous system compartment, their specificity for different types of schizophrenia and potential therapeutic strategies to prevent oxidative injuries in schizophrenia were discussed. Data were extracted from published literature found in Medline, Embase, Biosis, Cochrane and Web of Science, together with hand search of references. Search terms were: schizophrenia, oxidative stress, antipsychotics, antioxidants and fatty acids. Finding a sensitive, specific and non invasive biomarker of schizophrenia, which could be measured in peripheral tissue, still stays an important task. Antioxidant enzymes, markers of lipid peroxidation, oxidatively modified proteins and DNA are most commonly used. As it considers the supplemental therapy, according to our meta-analysis vitamin E could potentially improve tardive dyskinesia, while for the effect of therapy with polyunsaturated fatty acids there is no clear evidence. Oxidative stress is a part of the pathology in schizophrenia and appears as a promising field to develop new therapeutic strategies. There is a need for well designed, placebo controlled trials with supplementation therapy in schizophrenia.

Shown for reading. Its publisher allows quoting it, not republishing it.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

INTRODUCTION

Schizophrenia is a devastating mental disorder, expressed in the form of abnormal mental functions and disturbed behavior. It has a life-time prevalence of approximately 1% of the world’s population. The disorder has a bad outcome, regardless of different treatments (pharmacological, social, cognitive etc.). Cardinal symptoms of schizophrenia include positive and negative symptoms, and cognitive dysfunction and deterioration in social and occupational functioning. Schizophrenia is related to different neurodevelopmental, structural and behavioral abnormalities. It has been proposed that such abnormalities could originate from malfunctioning genes and/or non-genetic factors such as ethnicity, drug and alcohol abuse, life style, medications, pre-natal and neonatal infections, maternal malnutrition, complications during birth and many other factors. By inducing cellular metabolic stress these factors appear to increase the possibility of oxidative stress and damage. Oxidative stress is common to several psychiatric disorders. The mechanisms have been most widely studied in schizophrenia, employing various areas of oxidative research, including oxidative biomarkers assays, psychopharmacology, and clinical studies with antioxidants.

The scope of this article is to review the available literature on oxidative status in patients with schizophrenia, including reactive oxygen species and reactive nitrogen species production, antioxidant defense and influence of antipsychotic treatment. Furthermore, the possibility of measuring biomarkers in different tissues, their specificity for different types of schizophrenia, and potential therapeutic strategies to prevent reactive species (RS) mediated injuries in patients with schizophrenia will be examined. Data was obtained by searching the published literature: Medline, Embase, Biosis, Cochrane and Web of Science. Search terms were: schizophrenia, oxidative stress, antipsychotics, antioxidants, and fatty acids.

Oxidative Stress

Oxidative stress is defined as a disturbance in the prooxidant/antioxidant balance in favor of the former, leading to potential damage. Thus, diminished antioxidants and/or increased production of RS will result in oxidative damage of cell lipids, proteins, enzymes, carbohydrates and DNA. A growing body of evidence indicates that oxidative damage exists in schizophrenia. Although this may not be the main cause, oxidative damage has been suggested to be a common pathogenic process that contributes to declining course and poor outcome in schizophrenia.

Cells in the central nervous system (CNS) are more vulnerable to the toxic effects of RS than those in other organs of the body. Brain has a high rate of oxidative metabolic activity, high oxygen consumption, low levels of protective antioxidant enzymes, a high ratio of membrane surface area to cytoplasmic volume, and a neuronal anatomical network vulnerable to disruption. The high proportion of readily oxidizable membrane polyunsaturated fatty acids (PUFAs) make it more exposed to oxidative stress. Additionally, auto-oxidizable neurotransmitters, like dopamine (DA), epinephrine and norepinephrine, are present in excess in the brain. Metabolism of neurotransmitters generates large amounts of hydrogen peroxide (H2O2) and neuronal mitochondria can generate superoxide radical (O2•-). Furthermore, the presence of potentially toxic amino acids can trigger cell proteolysis. Of all the brain regions, the basal ganglia may be at particular risk for RS induced damage due to their large content of iron.

Antioxidative Defense

Human body has a complex defense system of antioxidant enzymes, including superoxide dismutase (SOD), glutathione peroxidase (GpX), and catalase (CAT). These enzymes block the initiation of RS chain reactions. The non-enzymatic antioxidant components are compounds such as glutathione (GSH), vitamin E, vitamin C and β-carotene, which react with RS and thereby prevent the propagation of chain reactions. Oxidative damage of the brain is suggested by increased lipid peroxidation products in the cerebrospinal fluid and plasma, and reduced membrane PUFAs in the brain and red blood cell (RBC) membranes. In response to increased RS formation and related membrane damage due to lipid peroxidation, the concentration of antioxidant enzymes can rise as a compensatory mechanism. Due to their specificity and affinity, in addition to their power of self-protection with redox elements in their active site and the possibility of amplification, antioxidant enzymes are the most important defence against RS.

Can Peripheral Biomarkers Reflect Status in the CNS?

Most measurements of oxidative stress in patients with schizophrenia have been made on peripheral tissues. There is a lack of information on oxidative processes in cerebrospinal fluid and brain. It must be stressed that traces of oxidative damage may originate from various sources in the body and consequently, such a peripheral indicator may not necessarily reflect the conditions of the oxidative stress parameters in the brain. Considering the size of the CNS in comparison to the other compartments of the human body, it seems reasonable to assume that changes in the levels of enzymes inside the brain can influence the enzyme plasma levels.

RBCs have often been used for evaluation of oxidative stress in patients with schizophrenia. Some illness-related abnormalities in RBCs may reflect equivalent abnormalities in the neurons, which are hard to examine in vivo. Because of its accessibility, the RBC membrane is commonly used as a “window” into the CNS. There are findings that a deficit identified in the RBC membrane is also present in the brain of patients with schizophrenia. Furthermore, alterations in phospholipids metabolism have been shown in post-mortem brain of schizophrenia patients. 31P magnetic resonance spectroscopy allows in vivo evaluation of phospholipids metabolism in the brain. Using this noninvasive technique Williamson et al. have demonstrated presence of membrane phospholipid abnormalities in schizophrenia, but they could not prove with certainty that these abnormalities are specific to schizophrenia. However, in a later 31P magnetic resonance study conducted on postmortem brain of patients with schizophrenia, compared to control there was no significant difference for any subclass of phospholipids.

Significantly lower levels of GSH, GpX and glutathione reductase (GR) were found in the brain of schizophrenia patients than in controls, which correlates with the peripheral measurements. On the other hand, there are studies with proton magnetic resonance reporting non significant reduction, or even an increase of GSH concentration in the brain.

There are also some suggestions that peripheral nitric oxide (NO) metabolites can be used as markers of CNS-dependent NO changes. Serum total nitrite was increased in a group of demyelinating diseases including multiple sclerosis, inflammatory neurological diseases and in AIDS patients.

Besides the theory that oxidative status in CNS influences the concentration of peripheral biomarkers, it should be stressed that also the reverse hypothesis is possible. In a study by Aytan et al., it has been demonstrated that peripheral oxidative stress can change oxidative status of CNS. In a rabbit model high cholesterol feeding caused an increase in serum malondialdehyde (MDA), which clearly correlated with an increase in protein oxidation parameters in the brain.

Due to heterogeneity of empirical evidence, currently there is no clear support to the value of peripheral biomarkers as markers of central oxidative status. It can be concluded that the results of studies on CNS (cerebrospinal fluid, postmortem or animals) show at least correlative tendencies with studies assaying biomarkers in erythrocytes, plasma or polymorphonuclears. The use of blood components in examining RS mediated pathology in schizophrenia appears reasonable. Peripheral biomarkers of RS mediated damage have also been suggested to be useful clinically in identifying patients with a high risk of developing different symptoms of schizophrenia or adverse events of antipsychotic treatment such as extrapyramidal syndrome.

Evaluation of Oxidative Status in Schizophrenia

Antioxidant enzymes such as SOD, GpX and CAT are most commonly measured for quantifying the antioxidative defense in schizophrenia, along with vitamin E and C levels. While the majority of studies have reported decreased antioxidant defense in patients with schizophrenia there are also some studies where the opposite has been reported. Several factors, such as differences in measuring techniques, differences in material tested, exposure to antipsychotic treatment, sampling of patients at different stages of the disease, differences in disease etiology and ethnic origin, lifestyle and dietary patterns, may be responsible for this discrepancy. Antioxidant enzymes are usually measured in RBCs. According to Halliwell et al., antioxidant enzyme levels can drop as a result of RBC ageing processes. Consequently these measurements reflects only RBC turnover in circulation. Additionally, MDA tends to have higher levels in summer compared to winter.

Antioxidant enzymes levels may be lower at the very early stages of psychotic disorder, and may further depend on the type of medication, the severity of psychopathology or environmental factors. On the other hand, it was suggested that decreased antioxidant defense probably exists later in patients on chronic treatment with antipsychotics. It was also indicated that haloperidol or other antipsychotics may not have a direct effect on antioxidant enzymes and that severity of symptomatology, may influence their activities, particularly of SOD and GpX.

Taken all together, the majority of studies confirm that oxidative stress and oxidative damage is present in schizophrenia, in never-medicated and early stage of disease and in treated and chronic stage as well.

Considerable attention has been focused on the determination of biomarkers of lipid peroxidation in schizophrenia. PUFAs peroxidation is a chain reaction with a large number of intermediates and end point molecules. It can be assayed in many ways, such as determination of lipid peroxides, isoprostanes, aldehydic end products like MDA and 4-hydroxynonenal (HNE), and by the determination of volatile hydrocarbons. The most frequently assayed marker of lipid peroxidation in schizophrenia are thiobarbituric acid related substances (TBARS). TBARS have been widely criticized for their poor specificity, but they are still acceptable and widely used in researches of lipid peroxidation. Results of the recent meta-analysis do not lessen belief in this parameter, at least within the context of schizophrenia research. Measurements of unsaturated aldehydes, such as HNE and acrolein, together with isoprostanes, exhaled hydrocarbons, and products of enzymatic peroxidation of arachidonic acid, such as tromboxane B2 and its metabolite 11-dehydrotromboxane B2 have been recommended.

Determination of oxidatively modified proteins seems to be relevant, considering their importance in cellular function, their critical roles in enzyme catalysis, ligand binding and signal transduction, and since damaged proteins can contribute to secondary damage of other molecules. Oxidative modification of proteins results in new functional groups and can seriously compromise cellular integrity. Protein carbonyls are an accepted index of protein oxidation and levels may be readily quantified in a variety of ways, including an enzyme-linked immunosorbent assay method. They are not specific markers of oxidative damage since bound aldehydes and glycated proteins are also measured. Furthermore, proteins can be damaged by compounds other than oxygen species and give products such as parahydroxyphenylacetaldehyde, 3-chlorotyrosine, 3,5-dichlorotyrosine, 3-bromotyrosine and 3-nitrotyrosine. 3-nitrotyrosine in human plasma proteins has been most commonly assayed. Oxidative modifications of proteins, measured by 3-nitrotyrosine and carbonyl groups, are proven to be significantly increased in schizophrenia.

Homocysteine has also been suggested as a potentially useful biomarker of oxidative stress in schizophrenia. The harmful effect of homocysteine arises from generation of RS during its catabolism, which could oxidize membrane lipids and proteins, including enzymes. In fact, it has been suggested that homocysteine may have a significant influence on the development and clinical symptoms of schizophrenia.

Investigation of DNA damage can lead to additional information as a prospective indicator of carcinogenic and mutagenic potential. Elevated levels of 8-hydroxy-2-deoxyguanosine resulting from DNA damage were determined in hippocampus of post-mortem schizophrenia patients. According to Halliwell et al., measurement of 8-hydroxy-2-deoxyguanosine is the most common method for evaluating DNA damage, however, artifactual results arising from isolation, preparation and analysis of DNA can easily occur. One of the proposed approaches is to measure oxidative DNA damage in the intact cell. An assay using antibodies has been developed, but it is only semiquantitative. 8-hydroxy-2-deoxyguanosine can also be measured in urine, but it is not possible to establish its tissue origin.

Additionally, less specific biomarkers which may reflect total oxidant and antioxidant status of plasma (TOS and TAS, respectively) as well as oxidative stress index (OSI) calculated as ratio of TOS and TAS, have been used to evaluate oxidant-antioxidant balance in schizophrenia.

A summary of studies evaluating biochemical alterations related to oxidative stress in patients with schizophrenia is given in Table 1.

Other potential biomarkers in schizophrenia, are less specific and include plasma arginase manganese blood platelets aggregability and apolipoprotein D level.

Can Different Types of Schizophrenia be Distinguished by Measuring Peripheral Signs?

Since the distinction between the negative and positive symptoms is based mainly on behavioral criteria, and since most individuals with schizophrenia exhibit a mixed positive-negative symptomatology, additional physiological and biochemical criteria would be valuable. Available data show that potential biomarkers include RBC properties, antioxidant activity, lipid hydrolyzing enzymes such as phospholipase A2, and phospholipid and fatty acid composition. These properties not only differ between patients with predominantly negative and positive symptoms, but many times also correlate with the symptom severity. Elevated levels of MDA and decreased PUFAs were found in patients with negative symptoms, indicating greater oxidative damage in this group of patients. Additionally, increased aggregation of RBC, O2•− production and S100 B protein level, but decreased activity of GpX were associated with negative symptoms. On the other hand, positive symptoms are correlated with increased level of SOD.

Antioxidative status and lipid peroxidation have been studied in patients from different schizophrenia subgroups, such as disorganized, paranoid and residual schizophrenia. The total antioxidant response was found to be higher in the paranoid subtype than in disorganized, residual or undifferentiated subtypes. SOD and GpX activities were significantly lower in paranoid and residual subtypes than in the disorganized subtype and the control group, while CAT activity was increased in all groups. The level of SOD in the residual group was higher than in the paranoid subtype. Treatment refractory patients with schizophrenia suffered from greater lipid peroxidation and neuronal damage than non-refractory patients. Gamma et al. studied the effects of clinical course of DSM-IV schizophrenia subtype on oxidative stress parameters. In comparison to deteoriated group, higher level of TBARS was associated with marked symptoms.

Although there is some empirical evidence that biomarkers of oxidative status correlate with symptoms in schizophrenia, there is not a clear correlation that could engage biomarkers in process of distinguishing different types of schizophrenia. Additional clinical studies are needed to further evaluate this theory.

Dopamine Oxidation

The pathology of schizophrenia is suggested to be related to oxidative damage. Oxidative stress plays a major role in the disease, even though it may not be the main cause.

Different mechanisms of oxidative stress in schizophrenia have been postulated. One of the most probable sources of RS is DA metabolism. DA has a dihydroquinone structure and can be under physiological conditions non-enzymatically oxidized by molecular oxygen to form hydrogen peroxide (H2O2) and the corresponding o-quinone. Non-enzymatic oxidation of catecholamines and PUFAs, combined with a deficient antioxidant system in the brain, may result in increased lipid peroxidation, which can influence the fluidity, integrity and permeability of membranes.

Oxidative deamination of DA by monoamine oxidase (MAO) can also lead to formation of H2O2 and 3,4-dihydroxyphenylacetaldehyde. Consequently, both the auto-oxidation and the MAO-mediated metabolism of DA involve the formation of H2O2, a compound that can easily be reduced in the presence of ferrous iron (Fe2+) to form, through the Fenton reaction, hydroxyl radical (OH•−). Hydroxyl radical is considered to be a highly damaging free radical for living cells. Due to high iron content in the brain, DA auto-oxidation is probably the predominant source of elevated hydrogen peroxide concentration.

Oxidative stress caused by elevated DA levels may enhance striatal glutamatergic neurotransmission leading to late-onset long-lasting permanent CNS damage.

There are also findings that NO may have a role in the pathophysiology of schizophrenia. NO is a gaseous neurotransmitter which is closely connected to dopaminergic and serotonergic neurotransmission. This provides a rationale for the involvement of NO and its pathway in schizophrenic disorders. Moreover, by interacting with O2•−, NO can produce peroxynitrite (ONOO−). This molecule can act as a neurotoxin by its interaction with the thiol groups on proteins as well as by decomposing into the highly reactive hydroxyl radical.

Mitochondrial Electron Transport Chain

Mitochondrial electron transport chain is an important source of RS. Mitochondria convert energy into adenosine triphosphate (ATP) by transport of protons across the inner mitochondrial membrane. The flow of electrons in the electron transport chain is a highly regulated process. The last step of this process is electron transport to oxygen molecule. Normally, oxygen is reduced to produce water. However, sometimes oxygen is prematurely and incompletely reduced to give the O2•−. This mechanism is well documented for Complex I and Complex III. Inhibition of chain complexes I, III and IV induces a massive RS production. Complex I is the most sensitive and its inactivation by 16% results in a significant increase in RS. There is evidence of abnormalities in the mitochondrial electron transport chain in an animal model and patients with schizophrenia.

Genetic Factors

With the appearance of new technologies and exact phenotypic sub-classification, the recognition of genetic bases of psychiatric diseases and assessment of disease related alterations is bringing psychiatric research to a new level. A genetic contribution to the pathogenesis of schizophrenia has been proposed. There is evidence that an impaired capacity to synthesize GSH due to genetic polymorphism is a vulnerability factor for schizophrenia. It has been reported that GSH levels are decreased by 27% in the cerebrospinal fluid and 52% in prefrontal complex of drug-naive patients with schizophrenia. Terpstra et al., and Matsuzawa et al., found reduction in GSH in brain, but the effect did not reach statistical significance. Additionally, Wood et al. conducted a study on first episode psychosis patients using magnetic resonance spectroscopy technique. Medial temporal lobe GSH concentrations were found to be 22% higher than those in control group. The authors concluded that the reason for the inconsistence with the results of the previous studies could be the difference in the stage of disease.

A positive association between schizophrenia and a functional polymorphism in the gene for manganese SOD has been shown in a sample of Japanese schizophrenia patients. A significant positive correlation between the total score on the Abnormal Involuntary Movements Scale (AIMS) and manganese SOD activity was found, which implies a general role of the oxidative stress-related genes in the pathogenesis of tardive dyskinesia (TD). Mukherjee et al. found that drug-naive first episode patients with schizophrenia have SOD activities significantly lower than those in healthy subjects, with no such differences in GpX and CAT activities. In another study, in first-episode patients the level of SOD was significantly lower, while CAT was significantly higher and GpX was unchanged.

The molecular mechanisms of the effective antipsychotic drugs and recent advances in neural research suggest that several genes could be involved in the disorder. Examination of the polymorphisms of six genes, D2 and D3 DA receptors, serotonin A2 receptor, the brain-derived neurotrophic factor, ciliary neurotrophic factor and neurotrophin-3, showed that there are significant differences between patients with schizophrenia and a control group regarding the D2 receptor gene in all patients, and D2 and neurotrophin-3 in female patients. The authors conclude that the differences in clinical presentation of schizophrenia between genders could have a genetic background.

Antipsychotic Treatment

It was suggested that the typical antipsychotic haloperidol, induces a six-fold increase in the levels of RS generated in mitochondria. The pyridinium ion metabolite derived from haloperidol might be cytotoxic, and is potentially related to drug induced extrapyramidal symptoms and cardiac functional disorder. Lipid peroxidation appears to be significantly higher after treatment with classical antipsychotics. Moreover, it was found that atypical antipsychotics may improve oxidative status, increasing antioxidant levels and decreasing oxidative damage markers such as TBARS. Whether this is related directly with the effect of drugs on antioxidant enzymes and lipid peroxidation or whether the effect is indirect, through alteration in O2•− and hydroxyl radical formation, remains to be determined. There appears to be a difference between typical antipsychotics, in terms of RS production after long-term treatment. Atypical antipsychotics show no change in lipid peroxidation product levels up to 90 days in treated rats. However, further treatment resulted in a significant increase in lipid peroxidation in the treatment with clozapine, ziprasidone and risperidone, but not with olanzapine. Additionally, clozapine was found to induce oxidative stress and pro-apoptotic gene expression in neutrophils of patients with schizophrenia. Some authors indicate that the changes in the activity of antioxidant enzymes and levels of biomarkers of oxidative damage, studied in patients with schizophrenia, are independent of antipsychotic treatment and may reflect the pathophysiological process of the disease. No effects of duration of the disease, gender or dose of chlorpromazine equivalents were observed.

THERAPEUTIC STRATEGIES FOR THE PREVENTION AND AMELIORATION OF OXIDATIVE DAMAGE

The endogenous antioxidant defense systems are not always entirely successful. The harmful effect in schizophrenia originating from RS could potentially be relieved by inactivation of RS by nutritional intake of antioxidants and essential fatty acids. This is supported by an experiment on animal model. In rats fed with PUFAs brain SOD activity increased.

Vitamin E is a potent lipid soluble antioxidant that can stop the spread of the chain reaction in the lipid part of the cell membrane. The concentration of vitamin E in peripheral nerves correlates with its concentration in plasma and depends on the dietary intake. Additionally, a deficit of vitamin E can attenuate the antioxidative defense. Currently, there is not enough evidence that supplementation with vitamin E improves symptoms of neuroleptic-induced TD.

Vitamin C is a water soluble antioxidant that scavenges RS. It can inhibit peroxidation of the membrane phospholipids, and can also improve regeneration of vitamin E. There is a 10-times higher concentration of vitamin C in the brain than in serum. In its oxidized form, vitamin C can cross the brain blood barrier, presumably via glucose transporter GLUT1, and is retained in the brain tissue. It is hypothesized that increased dietary intake of vitamin C influences its concentration in the brain.

There are a few molecules with antioxidant activity, such as melatonin, α-lipoic acid and coenzyme Q10, that can pass the blood brain barrier and ameliorate oxidative status in rats. Their use in neurodegenerative diseases, evaluation of their antioxidant activity and possible effects on other systems need to be further characterized.

In studies on patients with schizophrenia, the most commonly used antioxidants were vitamins E and C. Vitamin E is a lipid soluble antioxidant able to prevent the oxidative damage. Nevertheless, it has a small potential in preventing oxidative damage to cytosolic proteins, mitochondria, and nucleus, where most of the RS are produced. Therefore, it is reasonable to add vitamin C, a water soluble antioxidant. The adjunctive use of vitamins C and E in schizophrenia requires caution since a high dietary intake will result in pro-oxidant rather than antioxidant actions. In addition, supplementation with other antioxidants such as N-Acetyl Cysteine, rutin, Ginkgo biloba, melatonin, hydroxytyrosol, caffeic acid phenethyl ester, resveratrol and quercetin and lycopene has been suggested.

Among herbal supplemental antioxidative therapies used is schizophrenia, Ginkgo biloba was most widely studied. However, many studies were underpowered and poorly reported. Additionally, there is still some uncertainty which chemical compound was responsible for therapeutic effects. Two recently published meta-analyses demonstrated that treatment with Ginkgo biloba resulted in moderate improvement in total and negative symptoms of schizophrenia.

There is strong evidence that GSH concentration is decreased in cerebrospinal fluid, prefrontal cortex and postmortem caudate of patients with schizophrenia. Since cysteine is the rate-limiting precursor for GSH synthesis, it was proposed that treatment with N-acetyl cysteine could restore GSH levels. A recent randomized multicenter study involving 84 subjects demonstrated a positive effect of N-acetyl cysteine on total, general and negative component of PANSS and revealed an improvement of CGI-severity and CGI-improvement scales. Additionally, treatment with N-acetyl cysteine was associated with an amelioration of akathisia. No significant effect on PANSS positive subscale was observed. Bulut et al. reported a case of poorly responsive patient with schizophrenia, with significant improvement after supplementation with N-acetyl cysteine. A growing body of evidence suggests potential effectiveness of N-acetyl cysteine in schizophrenia, which has to be further confirmed.

Since nutritional intake of essential PUFAs affects the fatty acid composition of the neuronal cell membrane phospholipids, the addition of PUFAs, particularly omega-3 and omega-6, could be a solution for the recovery of damaged membrane structures.

The results of the use of vitamin E and omega-3 or 6- PUFAs are presented in Tables 2 and 3. Only randomized, double-blind clinical trials were selected for evaluating the influence of supplemental treatment on clinical symptoms in schizophrenia. All accessible studies with vitamin C treatment and treatment with various combinations of antioxidants and PUFAs are presented.

To evaluate the effect of vitamin E treatment in patients with schizophrenia we performed a meta-analysis. Selection criteria for inclusion of the study were study duration (at least 4 weeks) and adequately reported treatment effect (difference in Abnormal Involuntary Movement Scale (AIMS) score compared to baseline value). Of the studies reported in Table 2 seven studies met the inclusion criteria. From the extracted data weighted mean difference (WMD) with 95% confidence interval (95% CI) was calculated using Review Manager 4.2 (The Cochrane Collaboration, Oxford, UK). Random effect model was applied due to heterogeneity of the results of various studies. WMD of the improvement on AIMS was 1.92 (95% CI 0.60 to 3.24) suggesting significant treatment effect.

We find it interesting that two different studies of Adler et al., conducted with the same dose of vitamin E, had opposing results. The former study was conducted with a much smaller number of patients, 28 in comparison to 158 in the later study. Furthermore, the second study lasted much longer, 2 years in comparison to 12 weeks in the first study. In spite of this, the second study showed no significant influence of vitamin E on involuntary movement symptoms, as was observed in the first study. This suggests that there must be some difference in the chosen patient population. The authors themselves point out that when the first study was conducted, in 1993, therapy of schizophrenia was based mostly on the use of the classical antipsychotics while in 1999 atypical antipsychotics appeared in the prescribing patterns. Therefore, patients included in the later study were treated with classical or with atypical antipsychotics. Taking into account that there is considerable difference in the DA receptor blocking, the induction of RS production and in TD appearance between these two classes of antipsychotics, vitamin E would not be expected to have the same effect on symptoms improvement. The damaging potential and the symptoms observed differ considerably. Atypical antipsychotics induce much less TD in patients with schizophrenia. In spite of this, the Texas Medication Algorithm Project proposes that there is no reason to prefer atypical over classical antipsychotics in chronic schizophrenia, although opinion about this recommendation appears to be divided. Considering the fact that classical antipsychotics are still used in therapy of schizophrenia, further studies evaluating supplementation with vitamin E are recommended. Both studies by Adler et al. included very few female patients, making it a highly unrepresentative patient sample.

As far as vitamin C is concerned, there is very little data. Available studies with vitamin C treatment and treatment with combinations of vitamin C and vitamin E show a significant improvement in BPRS score and reduction in dyskinetic movement total score.

From the review of the effects of supplementation with PUFAs in schizophrenia, it can be concluded that they might improve mental state and movement disorder symptoms. This is mostly associated with omega-3 PUFAs, since there is only limited information on supplementation with omega-6 PUFAs. Meta-analysis of 5 eligible studies reported in Table 3 revealed insignificant improvement on PANSS score (WMD 2.85 95% CI -1.20 to 6.89). There are still too few data on the role of essential fatty acid supplementation in the treatment of patients with schizophrenia, and larger, well designed clinical studies need to be conducted.

Despite the suggestion that combined therapy with antioxidants and PUFAs is potentially more effective than monotherapy in patients with schizophrenia, only two studies with combined treatment were found. Positive results were observed in both of the studies which, however, were not controlled.

CONCLUSIONS

There is a growing body of evidence that oxidative stress is involved in the pathology of schizophrenia. Mechanisms involved include genetic susceptibility, catecholamine metabolism, and critical surroundings in the CNS (glutamate, iron, highly oxidizable fatty acids). Antipsychotic treatment, especially treatment with classical antipsychotics, also contributes to oxidative stress promotion.

Oxidative stress in schizophrenia can be evaluated with a wide spectrum of biomarkers. However, specific biomarkers based on a non-invasive sampling method, stable in biological materials, and easy to measure, has still to be discovered. It is suggested that measurements in blood can reflect oxidative status in CNS and can be clinically useful in identifying patients at high risk of developing adverse effects. However, this needs further confirmation. There are indications that different types of schizophrenia, and positive and negative symptoms, can be distinguished by the levels of biomarkers. This would be of great help in the diagnosis of schizophrenia and in predicting the course of disease. Attempts to ameliorate oxidative damage and therapeutically induced extrapyramidal syndrome are of considerable importance. The use of antioxidants and PUFAs in the treatment of schizophrenia has yielded some positive results, but still remains experimental. There is a need for larger, well designed clinical studies. Further studies need to be placebo-controlled with larger numbers of patients on standardized antipsychotic therapy and duration of disease. Since PUFAs administered together with antioxidant vitamins are potentially effective low cost supplemental treatment with few side effects, such therapy may become a significant advance in the treatment of schizophrenia.

References 153

  1. 1.

    Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am. Fam. Phys. 2007;75(12):1821-1829.

    Not in our library

  2. 2.

    Nestler E, Hyman S, Malenka R. Molecular neuropharmacology: A foundation of Clinical Neuroscience. 2001;383-407.

    Not in our library

  3. 3.

    Mahadik SP, Pillai A, Joshi S, Foster A. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int. Rev. Psychiatry. 2006;1(2):119-131.

    Not in our library10.1080/09540260600581993

  4. 4.

    Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, Wagh UV, Debsikdar VB, Mahadik SP. Decreased antioxidant enzymes and membrane essential poly-unsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 2003;121(2):109-122.

    Not in our library10.1016/s0165-1781(03)00220-8

  5. 5.

    Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 2008;11(6):851-876.

    Not in our library10.1017/s1461145707008401

  6. 6.

    Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. 2007;440-613.

    Not in our library

  7. 7.

    Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr. Res. 1996;19(1):1-17.

    Not in our library10.1016/0920-9964(95)00049-6

  8. 8.

    Perez-Neri I, Ramirez-Bermudez J, Montes S, Rios C. Possible mechanisms of neurodegeneration in schizophrenia. Neurochem. Res. 2006;31(10):1279-1294.

    Not in our library10.1007/s11064-006-9162-3

  9. 9.

    Fendri C, Mechri A, Khiari G, Othman A, Kerkeni A, Gaha L. [Oxidative stress involvement in schizophrenia pathophysiology: a review]. Encephale. 2006;32(2 Pt 1):244-252.

    Not in our library10.1016/s0013-7006(06)76151-6

  10. 10.

    Mukerjee S, Mahadik SP, Scheffer R, Correnti EE, Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr. Res. 1996;19(1):19-26.

    Not in our library10.1016/0920-9964(95)00048-8

  11. 11.

    Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2001;25(3):463-493.

    Not in our library10.1016/s0278-5846(00)00181-0

  12. 12.

    Michel TM, Thome J, Martin D, Nara K, Zwerina S, Tatschner T, Weijers HG, Koutsilieri E. Cu, Zn- and Mn-superoxide dismutase levels in brains of patients with schizophrenic psychosis. J. Neural. Transm. 2004;111(9):1191-1201.

    Not in our library10.1007/s00702-004-0160-9

  13. 13.

    Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 2002;58(1):1-10.

    Not in our library10.1016/s0920-9964(01)00334-6

  14. 14.

    Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging. 2001;18(9):685-716.

    Not in our library10.2165/00002512-200118090-00004

  15. 15.

    Halliwell B. Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 2006;97(6):1634-1658.

    Not in our library10.1111/j.1471-4159.2006.03907.x

  16. 16.
    Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options · 2009
    No notice
  17. 17.

    Halliwell B. Reactive species and antioxidants. Redox biology is a fundamental theme of aerobic life. Plant Physiol. 2006;141(2):312-322.

    Not in our library10.1104/pp.106.077073

  18. 18.

    Dorfman-Etrog P, Hermesh H, Prilipko L, Weizman A, Munitz H. The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: an open label study. Eur. Neuropsychopharmacol. 1999;9(6):475-477.

    Not in our library10.1016/s0924-977x(99)00015-2

  19. 19.

    Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress inducedneurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology. 2001;40(8):959-975.

    Not in our library10.1016/s0028-3908(01)00019-3

  20. 20.

    Harris ED. Regulation of antioxidant enzymes. FASEB J. 1992;6(9):2675-2683.

    Not in our library10.1096/fasebj.6.9.1612291

  21. 21.

    Akyol O, Herken H, Uz E, Fadillioglu E, Unal S, Sogut S, Ozyurt H, Savas HA. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog. Neuropsy-chopharmacol. Biol. Psychiatry. 2002;26(5):995-1005.

    Not in our library10.1016/s0278-5846(02)00220-8

  22. 22.

    Yanik M, Vural H, Kocyigit A, Tutkun H, Zoroglu SS, Herken H, Savas HA, Koylu A, Akyol O. Is the arginine-nitric oxide pathway involved in the pathogenesis of schizophrenia? Neuropsychobiology. 2003;47(2):61-65.

    Not in our library10.1159/000070010

  23. 23.

    Do K, Bovet P, Cuenod M. Schizophrenia: Glutathione deficit as a new vulnerability factor for disconectivity sindrome. Schweiz. Arch. Psyciatr. 2004;155(8):375-385.

    Not in our library

  24. 24.

    Grima G, Benz B, Parpura V, Cuenod M, Do KQ. Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr. Res. 2003;62(3):213-224.

    Not in our library10.1016/s0920-9964(02)00405-x

  25. 25.

    Do KQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, Hell D, Holsboer F, Boesiger P, Cuenod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J. Neurosci. 2000;12(10):3721-3728.

    Not in our library10.1046/j.1460-9568.2000.00229.x

  26. 26.

    Dietrich-Muszalska A, Olas B, Rabe-Jablonska J. Oxidative stress in blood platelets from schizophrenic patients. Platelets. 2005;16(7):386-391.

    Not in our library10.1080/09537100500128872

  27. 27.

    Berger GE, Smesny S, Amminger GP. Bioactive lipids in schizophrenia. Int. Rev. Psychiatry. 2006;18(2):85-98.

    Not in our library10.1080/09540260600583072

  28. 28.

    Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res. 2000;42(1):7-17.

    Not in our library10.1016/s0920-9964(99)00095-x

  29. 29.

    Yao JK, van Kammen DP, Gurklis J. Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures. Schizophr. Res. 1994;13(3):227-232.

    Not in our library10.1016/0920-9964(94)90046-9

  30. 30.

    Williamson PC, Brauer M, Leonard S, Thompson T, Drost D. 31P magnetic resonance spectroscopy studies in schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids. 1996;55(1-2):115-118.

    Not in our library10.1016/s0952-3278(96)90155-6

  31. 31.

    Pearce JM, Komoroski RA, Mrak RE. Phospholipid composition of postmortem schizophrenic brain by 31P NMR spectroscopy. Magn. Reson. Med. 2009;61(1):28-34.

    Not in our library10.1002/mrm.21820

  32. 32.

    Terpstra M, Vaughan TJ, Ugurbil K, Lim KO, Schulz SC, Gruetter R. Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia. Magma. 2005;18(5):276-282.

    Not in our library10.1007/s10334-005-0012-0

  33. 33.

    Wood SJ, Berger GE, Wellard RM, Proffitt TM, McCon-chie M, Berk M, McGorry PD, Pantelis C. Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation. Neurobiol. Dis. 2009;33(3):354-357.

    Not in our library10.1016/j.nbd.2008.11.018

  34. 34.
    Negative Correlation between Brain Glutathione Level and Negative Symptoms in Schizophrenia: A 3T 1H-MRS Study · 2008
    No notice
  35. 35.

    Aytan N, Jung T, Tamturk F, Grune T, Kartal-Ozer N. Oxidative stress related changes in the brain of hypercholesterolemic rabbits. Biofactors. 2008;33(3):225-236.

    Not in our library10.1002/biof.5520330308

  36. 36.

    Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am. J. Psychiatry. 1998;155(9):1207-1213.

    Not in our library10.1176/ajp.155.9.1207

  37. 37.

    Songur A, Sarsilmaz M, Sogut S, Ozyurt B, Ozyurt H, Zararsiz I, Turkoglu A. Hypotalamic superoxide dismutaze, xanthine oxidase, nitric oxide, and malondialdehyde in rats fed with fish w-3 fatty acids. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2004;28:693-698.

    Not in our library10.1016/j.pnpbp.2004.05.006

  38. 38.

    Nishioka N, Arnold S. Evidence of oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. Am. J. Geriatr. Psychiatry. 2004;12(2):167-175.

    Not in our library

  39. 39.

    Ponizovsky AM, Barshtein G, Bergelson LD. Biochemical alterations of erythrocytes as an indicator of mental disorders: an overview. Harv. Rev. Psychiatry. 2003;11(6):317-332.

    Not in our library

  40. 40.

    Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol. Psychiatry. 1997;42(1):1-5.

    Not in our library10.1016/s0006-3223(96)00302-2

  41. 41.

    D'Souza B, D'Souza V. Oxidative injury and antioxidant vitamins E and C in Schizophrenia. Indian J. Clin. Biochem. 2003;18(1):87-90.

    Not in our library10.1007/bf02867671

  42. 42.

    Dadheech G, Mishra S, Gautam S. Oxidative stress, alphatocopherol, ascorbic acid and reduced glutathione status in schizophrenics. Indian J. Clin. Biochem. 2006;21(2):34-38.

    Not in our library10.1007/bf02912908

  43. 43.

    Abdalla DS, Monteiro HP, Oliveira JA, Bechara EJ. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clin. Chem. 1986;32(5):805-807.

    Not in our library

  44. 44.

    Ben Othmen L, Mechri A, Fendri C, Bost M, Chazot G, Gaha L, Kerkeni A. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008;32(1):155-159.

    Not in our library10.1016/j.pnpbp.2007.08.003

  45. 45.

    Kropp S, Kern V, Lange K, Degner D, Hajak G, Kornhuber J, Ruther E, Emrich HM, Schneider U, Bleich S. Oxidative stress during treatment with first- and second-generation antipsychotics. J. Neuropsychiatry. Clin. Neurosci. 2005;17(2):227-231.

    Not in our library10.1176/jnp.17.2.227

  46. 46.

    Li HC, Chen QZ, Ma Y, Zhou JF. Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study. J. Zhejiang Univ. Sci. B. 2006;7(12):981-986.

    Not in our library10.1631/jzus.2006.b0981

  47. 47.

    Pavlovic D, Tamburic V, Stojanovic I. Oxidative stress as marker of possitive symptoms in schizophrenia. Facta Univ. 2002;9(2):157-161.

    Not in our library

  48. 48.

    Sirota P, Gavrieli R, Wolach B. Overproduction of neutrophil radical oxygen species correlates with negative symptoms in schizophrenic patients: parallel studies on neutrophil chemotaxis, supe-roxide production and bactericidal activity. Psychiatry Res. 2003;121(2):123-132.

    Not in our library10.1016/s0165-1781(03)00222-1

  49. 49.

    Sivrioglu EY, Kirli S, Sipahioglu D, Gursoy B, Sarandol E. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007;31(7):1493-1499.

    Not in our library10.1016/j.pnpbp.2007.07.004

  50. 50.

    Strassnig M, Singh Brar J, Ganguli R. Dietary fatty acid and antioxidant intake in community-dwelling patients suffering from schizophrenia. Schizophr. Res. 2005;76(2-3):343-351.

    Not in our library10.1016/j.schres.2005.03.002

  51. 51.

    Ustundag B, Atmaca M, Kirtas O, Selek S, Metin K, Tezcan E. Total antioxidant response in patients with schizophrenia. Psychiatry Clin. Neurosci. 2006;60(4):458-464.

    Not in our library10.1111/j.1440-1819.2006.01532.x

  52. 52.
    Altered Glutathione Redox State in Schizophrenia · 2006
    No notice
  53. 53.

    Yao JK, Reddy R, van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res. 1998;80(1):29-39.

    Not in our library10.1016/s0165-1781(98)00051-1

  54. 54.

    Zhang X, Zhou D, Cao L, Wu G. The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl.). 2006;188(1):12-17.

    Not in our library10.1007/s00213-006-0476-2

  55. 55.

    Dakhale G, Khanzode S, Khanzode S, Saoji A, Khobragade L, Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology. 2004;49(4):205-209.

    Not in our library10.1159/000077368

  56. 56.

    Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem. Funct. 2002;20(2):171-175.

    Not in our library10.1002/cbf.940

  57. 57.

    Surapaneni K. Status of lipid peroxidation, glutathione, ascorbic acid, vitamin E and antioxidant enzymes in schizophrenic patients. J. Clin. Diagn. Res. 2007;1(2):39-44.

    Not in our library

  58. 58.

    Rukmini M, D'Souza B, D'Souza V. Superoxide dismutase and catalase activities and their correlation with malondialdehyde in schizophrenic patients. Indian J. Clin. Biochem. 2004;19(2):114-118.

    Not in our library10.1007/bf02894268

  59. 59.

    Altuntas I, Aksoy H, Coskun I, Caykoylu A, Akcay F. Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clin. Chem. Lab. Med. 2000;38(12):1277-1281.

    Not in our library10.1515/cclm.2000.201

  60. 60.

    Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br. J. Pharmacol. 2004;142(2):231-255.

    Not in our library10.1038/sj.bjp.0705776

  61. 61.

    Morera AL, Intxausti A, Abreu-Gonzalez P. Winter/summer seasonal changes in malondialdehyde formation as a source of variance in oxidative stress schizophrenia research. World J. Biol. Psychiatry. 2009;10(4 Pt 2):576-580.

    Not in our library10.1080/15622970801901802

  62. 62.

    Yao JK, Reddy R, van Kammen DP. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res. 2000;97(2-3):137-151.

    Not in our library10.1016/s0165-1781(00)00230-4

  63. 63.

    Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Haile CN, Kosten TA, Kosten TR. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J. Clin. Psychiatry. 2007;68(5):754-760.

    Not in our library10.4088/jcp.v68n0513

  64. 64.

    Young J, McKinney S, Ross B, Wahle K, Boyle S. Biomarkers of oxidative stress in schizophrenic and control subjects Prostaglandins Leukot. Essent. Fatty Acids. 2007;76:73-85.

    Not in our library10.1016/j.plefa.2006.11.003

  65. 65.

    Grignon S, Chianetta JM. Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007;31(2):365-369.

    Not in our library10.1016/j.pnpbp.2006.09.012

  66. 66.

    Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog. Lipid. Res. 2003;42(4):318-343.

    Not in our library10.1016/s0163-7827(03)00014-6

  67. 67.

    Dietrich-Muszalska A, Olas B. Isoprostenes as indicators of oxidative stress in schizophrenia. World J. Biol. Psychiatry. 2007;1-7.

    Not in our library10.1080/15622970701361263

  68. 68.

    Buss H, Chan TP, Sluis KB, Domigan NM, Winterbourn CC. Protein carbonyl measurement by a sensitive ELISA method. Free Radic. Biol. Med. 1997;23(3):361-366.

    Not in our library10.1016/s0891-5849(97)00104-4

  69. 69.

    Dietrich-Muszalska A, Olas B. Modifications of blood platelet proteins of patients with schizophrenia. Platelets. 2009;20(2):90-96.

    Not in our library10.1080/09537100802641499

  70. 70.

    Dietrich-Muszalska A, Olas B, Glowacki R, Bald E. Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology. 2009;59(1):1-7.

    Not in our library10.1159/000202822

  71. 71.

    Akanji AO, Ohaeri JU, Al-Shammri SA, Fatania HR. Associations of blood homocysteine concentrations in Arab schizophrenic patients. Clin. Biochem. 2007;40(13-14):1026-1031.

    Not in our library10.1016/j.clinbiochem.2007.06.001

  72. 72.

    Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci. 2003;26(3):137-146.

    Not in our library10.1016/s0166-2236(03)00032-8

  73. 73.

    Halliwell B. Why and how should we measure oxidative DNA damage in nutritional studies? How far have we come? Am. J. Clin. Nutr. 2000;72:1082-1087.

    Not in our library10.1093/ajcn/72.5.1082

  74. 74.

    Psimadas D, Messini-Nikolaki N, Zafiropoulou M, Fortos A, Tsilimigaki S, Piperakis SM. DNA damage and repair efficiency in lymphocytes from schizophrenic patients. Cancer Lett. 2004;204(1):33-40.

    Not in our library10.1016/j.canlet.2003.09.022

  75. 75.

    Virit O, Altindag A, Yumru M, Dalkilic A, Savas HA, Selek S, Erel O, Herken H. A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology. 2009;60(2):87-93.

    Not in our library10.1159/000239684

  76. 76.

    Pazvantoglu O, Selek S, Okay IT, Sengul C, Karabekiroglu K, Dilbaz N, Erel O. Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile. Psychiatry Clin. Neurosci. 2009;63(5):693-700.

    Not in our library10.1111/j.1440-1819.2009.02015.x

  77. 77.

    Yilmaz N, Herken H, Cicek HK, Celik A, Yurekli M, Akyol O. Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. Med. Princ. Pract. 2007;16(2):137-141.

    Not in our library10.1159/000098367

  78. 78.

    Dietrich-Muszalska A, Olas B. The changes of aggregability of blood platelets in schizophrenia. World J. Biol. Psychiatry. 2009;10(2):171-176.

    Not in our library10.1080/15622970701557993

  79. 79.

    Yao JK, Thomas EA, Reddy RD, Keshavan MS. Association of plasma apolipoproteins D with RBC membrane arachidonic acid levels in schizophrenia. Schizophr. Res. 2005;72(2-3):259-266.

    Not in our library10.1016/j.schres.2004.05.007

  80. 80.

    Ozcankaya D, Eren I. Activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX) and levels of malondialdehyde (MDA) reduced gluthatione (GSH) in schizophrenia patients with negative or positive symptoms. Biomed. Res. 2001;12(3):225-230.

    Not in our library

  81. 81.

    Sarandol A, Kirli S, Akkaya C, Altin A, Demirci M, Sarandol E. Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007;31(6):1164-1169.

    Not in our library10.1016/j.pnpbp.2007.03.008

  82. 82.

    Evans D, Parikh V, Khan M, CCoussons Buckley P, Mahadik S. Red blood cell membrane essential fatty acid metabolism in early psychotic. Prostaglandins Leukot. Essent. Fatty Acids. 2003;69:393-399.

    Not in our library10.1016/j.plefa.2003.08.010

  83. 83.

    Yamada K, Kanba S, Anamizu S. Low superoxide dismutase activity in schizophrenic patients with tardive dyskinesia. Psychol. Med. 1997;27(5):1223-1225.

    Not in our library10.1017/s0033291797005114

  84. 84.

    Medina-Hernandez V, Ramos-Loyo J, Luquin S. Increased lipid peroxidation and neuron specific enolase in treatment refractory schizophrenics. J. Psychiatr. Res. 2007;41(8):652-658.

    Not in our library10.1016/j.jpsychires.2006.02.010

  85. 85.

    Gama CS, Salvador M, Andreazza AC, Lobato MI, Berk M, Kapczinski F, Belmonte-De-Abreu PS. Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. Neurosci. Lett. 2008;433(3):270-273.

    Not in our library10.1016/j.neulet.2008.01.018

  86. 86.

    Smythies JR. Oxidative reactions and schizophrenia: a review-discussion. Schizophr. Res. 1997;24(3):357-364.

    Not in our library10.1016/s0920-9964(97)00005-4

  87. 87.

    Masserano JM, Baker I, Venable D, Gong L, Zullo SJ, Merril CR, Wyatt RJ. Dopamine induces cell death, lipid peroxidation and DNA base damage in a catecholaminergic cell line derived from the central nervous system. Neurotox. Res. 2000;1(3):171-179.

    Not in our library10.1007/bf03033288

  88. 88.

    Ben-Shachar D, Zuk R, Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J. Neurochem. 1995;64(2):718-723.

    Not in our library10.1046/j.1471-4159.1995.64020718.x

  89. 89.

    Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 2001;65(2):135-172.

    Not in our library10.1016/s0301-0082(01)00003-x

  90. 90.

    Hermida-Ameijeiras A, Mendez-Alvarez E, Sanchez-Iglesias S, Sanmartin-Suarez C, Soto-Otero R. Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions. Neurochem. Int. 2004;45(1):103-116.

    Not in our library10.1016/j.neuint.2003.11.018

  91. 91.

    Kopin IJ. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol. Rev. 1985;37(4):333-364.

    Not in our library

  92. 92.

    Mazzio EA, Soliman KF. Glioma cell antioxidant capacity relative to reactive oxygen species produced by dopamine. J. Appl. Toxicol. 2004;24(2):99-106.

    Not in our library10.1002/jat.954

  93. 93.

    Linert W, Jameson GN. Redox reactions of neurotransmitters possibly involved in the progression of Parkinson's Disease. J. Inorg. Biochem. 2000;79(1-4):319-326.

    Not in our library10.1016/s0162-0134(99)00238-x

  94. 94.

    Taneli F, Pirildar S, Akdeniz F, Uyanik BS, Ari Z. Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch. Med. Res. 2004;35(5):401-405.

    Not in our library10.1016/j.arcmed.2004.06.002

  95. 95.

    Bernstein HG, Bogerts B, Keilhoff G. The many faces of nitric oxide in schizophrenia. A review. Schizophr. Res. 2005;78(1):69-86.

    Not in our library10.1016/j.schres.2005.05.019

  96. 96.

    Herken H, Uz E, Ozyurt H, Akyol O. Red blood cell nitric oxide levels in patients with schizophrenia. Schizophr. Res. 2001;52(3):289-290.

    Not in our library10.1016/s0920-9964(00)00169-9

  97. 97.

    Reif A, Herterich S, Strobel A, Ehlis AC, Saur D, Jacob CP, Wienker T, Topner T, Fritzen S, Walter U, Schmitt A, Fallgatter AJ, Lesch KP. A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefron-tal cortex function. Mol. Psychiatry. 2006;11(3):286-300.

    Not in our library10.1038/sj.mp.4001779

  98. 98.

    Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Srimal RC, Seth PK, Dikshit M. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berl). 2001;158(2):140-145.

    Not in our library10.1007/s002130100860

  99. 99.

    Sipos I, Tretter L, Adam-Vizi V. Quantitative relationship between inhibition of respiratory complexes and formation of reactive oxygen species in isolated nerve terminals. J. Neurochem. 2003;84(1):112-118.

    Not in our library10.1046/j.1471-4159.2003.01513.x

  100. 100.

    Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS, Karp NA, Hester S, Tkachev D, Mimmack ML, Yolken RH, Webster MJ, Torrey EF, Bahn S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry. 2004;9(7):684-697-643.

    Not in our library10.1038/sj.mp.4001511

  101. 101.

    Frey BN, Valvassori SS, Gomes KM, Martins MR, Dal-Pizzol F, Kapczinski F, Quevedo J. Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure. Brain Res. 2006;1097:224-229.

    Not in our library10.1016/j.brainres.2006.04.076

  102. 102.

    Rezin GT, Amboni G, Zugno AI, Quevedo J, Streck EL. Mitochondrial dysfunction and psychiatric disorders. Neurochem. Res. 2009;34(6):1021-1029.

    Not in our library10.1007/s11064-008-9865-8

  103. 103.

    Casademont J, Garrabou G, Miro O, Lopez S, Pons A, Bernardo M, Cardellach F. Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients. J. Clin. Psychopharmacol. 2007;27(3):284-288.

    Not in our library10.1097/jcp.0b013e318054753e

  104. 104.

    Stober G, Ben-Shachar D, Cardon M, Falkai P, Fonteh AN, Gawlik M, Glenthoj BY, Grunblatt E, Jablensky A, Kim YK, Kornhuber J, McNeil TF, Muller N, Oranje B, Saito T, Saoud M, Schmitt A, Schwartz M, Thome J, Uzbekov M, Durany N, Riederer P. Schizophrenia from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J. Biol. Psychiatry. 2009;10(2):127-155.

    Not in our library10.1080/15622970902898980

  105. 105.

    Virgos C, Martorell L, Valero J, Figuera L, Civeira F, Joven J, Labad A, Vilella E. Association study of schizophrenia with polymorphisms at six candidate genes. Schizophr. Res. 2001;49(1-2):65-71.

    Not in our library10.1016/s0920-9964(00)00106-7

  106. 106.

    Thelma BK, Tiwari AK, Deshpande SN, Lerer B, Nimgaonkar VL. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: role of oxidative stress pathway genes. Schizophr. Res. 2007;92(1-3):278-279.

    Not in our library10.1016/j.schres.2006.12.019

  107. 107.

    Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, Deppen P, Preisig M, Ruiz V, Steullet P, Tosic M, Werge T, Cuenod M, Do KQ. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc. Natl. Acad. Sci. USA. 2007;104(42):16621-16626.

    Not in our library10.1073/pnas.0706778104

  108. 108.

    Shinkai T, Muller DJ, De Luca V, Shaikh S, Matsumoto C, Hwang R, King N, Trakalo J, Potapova N, Zai G, Hori H, Ohmori O, Meltzer HY, Nakamura J, Kennedy JL. Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia. Psychiatry Res. 2006;141(2):123-128.

    Not in our library10.1016/j.psychres.2004.06.023

  109. 109.

    Hori H, Ohmori O, Shinkai T, Kojima H, Okano C, Suzuki T, Nakamura J. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology. 2000;23(2):170-177.

    Not in our library10.1016/s0893-133x(99)00156-6

  110. 110.

    Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J. Neurochem. 1998;71(3):1002-1012.

    Not in our library10.1046/j.1471-4159.1998.71031002.x

  111. 111.

    Iwahashi K, Anemo K, Nakamura K, Fukunishi I, Igarashi K. Analysis of the metabolism of haloperidol and its neurotoxic pyridinium metabolite in patients with drug-induced parkinsonism. Neuropsychobiology. 2001;44(3):126-128.

    Not in our library10.1159/000054931

  112. 112.

    Reinke A, Martins MR, Lima MS, Moreira JC, Dal-Pizzol F, Quevedo J. Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci. Lett. 2004;372(1-2):157-160.

    Not in our library10.1016/j.neulet.2004.09.032

  113. 113.

    Wei Z, Bai O, Richardson JS, Mousseau DD, Li XM. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J. Neurosci. Res. 2003;73(3):364-368.

    Not in our library10.1002/jnr.10668

  114. 114.

    Pillai A, Parikh V, Terry AV, Mahadik SP. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 2007;41(5):372-386.

    Not in our library10.1016/j.jpsychires.2006.01.011

  115. 115.

    Fehsel K, Loeffler S, Krieger K, Henning U, Agelink M, Kolb-Bachofen V, Klimke A. Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients. J. Clin. Psychopharmacol. 2005;25(5):419-426.

    Not in our library10.1097/01.jcp.0000177668.42640.fe

  116. 116.

    Soares K, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev. 2001;4.

    Not in our library10.1002/14651858.cd000209

  117. 117.

    Nicolaus M, Hildegard S, Volker A, Erfurth A. Severe tardive dyskinesia in affective disorders:treatment with vitamin E and C. Neuropsychobiology. 2002;46(1):28-30.

    Not in our library10.1159/000068019

  118. 118.

    Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush AI. N-acetyl cysteine as a glutathione precursor for schizophreniaa double-blind, randomized, placebo-controlled trial. Biol. Psychiatry:. 2008;64(5):361-368.

    Not in our library10.1016/j.biopsych.2008.03.004

  119. 119.

    Bulut M, Savas HA, Altindag A, Virit O, Dalkilic A. Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia. World J. Biol. Psychiatry. 2009;10(4 Pt 2):626-628.

    Not in our library10.1080/15622970903144004

  120. 120.

    Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, Bovet P, Bush AI, Conus P, Copolov D, Fornari E, Meuli R, Solida A, Vianin P, Cuenod M, Buclin T, Do KQ. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology. 2008;33(9):2187-2199.

    Not in our library10.1038/sj.npp.1301624

  121. 121.

    Dodd S, Dean O, Copolov DL, Malhi GS, Berk M. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin. Biol. Ther. 2008;8(12):1955-1962.

    Not in our library10.1517/14728220802517901

  122. 122.

    Bishnoi M, Chopra K, Kulkarni S. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. Fundam. Clin. Pharmacol. 2007;21:521-529.

    Not in our library10.1111/j.1472-8206.2007.00512.x

  123. 123.

    Singh V, Singh SP, Chan K. Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. Int. J. Neuropsychopharmacol. 2010;13(2):257-271.

    Not in our library10.1017/s1461145709990654

  124. 124.

    Zhang X, Zhou D, Su J, Zhang P. The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. J. Clin. Psychopharmacol. 2001;21:85-88.

    Not in our library10.1097/00004714-200102000-00015

  125. 125.

    Atmaca M, Tezcan E, Kugolu M, Ustundang B, Kirtas O. The effect of extract of Ginkgo biloba addition to Olanzapine therapeutic effect and antioxidant enzyme levels in patients with schizophrenia. Psychiatry Clin. Neurosci. 2005;59(6):652-656.

    Not in our library10.1111/j.1440-1819.2005.01432.x

  126. 126.

    Rathbone J, Zhang L, Zhang M, Xia J, Liu X, Yang Y. Chinese herbal medicine for schizophrenia. Cochrane Database Syst. Rev. 2005;4.

    Not in our library10.1002/14651858.cd003444.pub2

  127. 127.

    Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, Elizur A, Weizman R. Melatonin treatment for tardive dyskinesia: a double-blind, placebo controlled, crossover study. Arch. Gen. Psychiatry. 2001;58(11):1049-1052.

    Not in our library10.1001/archpsyc.58.11.1049

  128. 128.

    Ortiz GG, Benitez-King GA, Rosales-Corral SA, Pacheco-Moises FP, Velazquez-Brizuela IE. Cellular and biochemical actions of melatonin which protect against free radicals: role in neurodegenerative disorders. Curr. Neuropharmacol. 2008;6(3):203-214.

    Not in our library10.2174/157015908785777201

  129. 129.

    Maldonado MD, Reiter RJ, Perez-San-Gregorio MA. Melatonin as a potential therapeutic agent in psychiatric illness. Hum. Psychopharmacol. 2009;24(5):391-400.

    Not in our library10.1002/hup.1032

  130. 130.

    Young J, Wahle K, Boyle S. Cytoprotective effects of phenolic antioxidants and essential fatty acids in human blodd monocyte and neuroblastoma cell lines: Surrogates for neurological damage in vivo. Prostaglandins Leukot. Essent. Fatty Acids. 2007;78(1):45-59.

    Not in our library10.1016/j.plefa.2007.10.005

  131. 131.

    Ozyurt B, Ozyrut H, Akpolat N, Erdogan H, Sarsilmaz M. Oxidative stress in prefrontal cortex of ret exposed to MK-801 and protective effects of CAPE. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007;31:832-838.

    Not in our library10.1016/j.pnpbp.2007.01.029

  132. 132.

    Dietrich-Muszalska A, Olas B. Inhibitory effects of polyphenol compounds on lipid peroxidation caused by antipsychotics (haloperidol and amisulpride) in human plasma in vitro. World J. Biol. Psychiatry. 2009;1-6.

    Not in our library10.1080/15622970902718790

  133. 133.

    Rao A, Rao L. Lycopene and human health. Curr. Top. Nutraceutical Res. 2004;2(3):127-136.

    Not in our library

  134. 134.

    Rao A, Balachandran B. Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr. Neurosci. 2002;5(5):291-309.

    Not in our library10.1080/1028415021000033767

  135. 135.

    Mazza M, Pomponi M, Janiri L, Bria P, Mazza S. Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: an overview. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007;31(1):12-26.

    Not in our library10.1016/j.pnpbp.2006.07.010

  136. 136.

    Sarsilmaz M, Songur A, Ozyurt H, Kus I, Ozen A, Ozyurt B, Sogut S, Akyol O. Potential role of dietary w-3 essential fatty acids on some oxidant/antioxidant parameters in rats’ corpus striatum. Prostaglandins Leukot. Essent. Fatty Acids. 2003;69:253-259.

    Not in our library10.1016/s0952-3278(03)00107-8

  137. 137.

    Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol. Psychiatry. 2000;1:8-21.

    Not in our library10.1016/s0006-3223(99)00092-x

  138. 138.

    Adler LA, Peselow E, Rotrosen J, Duncan E, Lee M, Rosenthal M, Angrist B. Vitamin E treatment of tardive dyskinesia. Am. J. Psychiatry. 1993;150(9):1405-1407.

    Not in our library10.1176/ajp.150.9.1405

  139. 139.

    Adler LA, Rotrosen J, Edson R, Lavori P, Lohr J, Hitzemann R, Raisch D, Caligiuri M, Tracy K. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch. Gen. Psychiatry. 1999;56(9):836-841.

    Not in our library10.1001/archpsyc.56.9.836

  140. 140.

    Dabiri LM, Pasta D, Darby JK, Mosbacher D. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am. J. Psychiatry. 1994;151(6):925-926.

    Not in our library10.1176/ajp.151.6.925

  141. 141.

    Elkashef AM, Ruskin PE, Bacher N, Barrett D. Vitamin E in the treatment of tardive dyskinesia. Am. J. Psychiatry. 1990;147(4):505-506.

    Not in our library10.1176/ajp.147.4.505

  142. 142.

    Lam LC, Chiu HF, Hung SF. Vitamin E in the treatment of tardive dyskinesia: a replication study. J. Nerv. Ment. Dis. 1994;182(2):113-114.

    Not in our library10.1097/00005053-199402000-00009

  143. 143.

    Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J. Clin. Psychiatry. 1996;57(4):167-173.

    Not in our library

  144. 144.

    Sajjad SH. Vitamin E in the treatment of tardive dyskinesia: a preliminary study over 7 months at different doses. Int. Clin. Psychopharmacol. 1998;13(4):147-155.

    Not in our library10.1097/00004850-199807000-00001

  145. 145.

    Rosenheck RA. Pharmacotherapy of first-episode schizophrenia. Lancet. 2008;371(9618):1048-1049.

    Not in our library10.1016/s0140-6736(08)60463-8

  146. 146.

    Dakhale GN, Khanzode SD, Khanzode SS, Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl). 2005;182(4):494-498.

    Not in our library10.1007/s00213-005-0117-1

  147. 147.

    Joy S, Mumby-Croft R, Joy L. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst. Rev. 2006;2.

    Not in our library10.1002/14651858.cd001257.pub2

  148. 148.

    Emsley R, Niehaus DJ, Koen L, Oosthuizen PP, Turner HJ, Carey P, van Rensburg SJ, Maritz JS, Murck H. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr. Res. 2006;84(1):112-120.

    Not in our library10.1016/j.schres.2006.03.023

  149. 149.

    Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Psychiatry. 2001;158(12):2071-2074.

    Not in our library10.1176/appi.ajp.158.12.2071

  150. 150.

    Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr. Res. 2001;49(3):243-251.

    Not in our library10.1016/s0920-9964(00)00083-9

  151. 151.

    Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatr. Res. 2002;36(1):7-18.

    Not in our library10.1016/s0022-3956(01)00048-6

  152. 152.

    Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry. 2002;159(9):1596-1598.

    Not in our library10.1176/appi.ajp.159.9.1596

  153. 153.

    Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr. Res. 2003;62(3):195-204.

    Not in our library10.1016/s0920-9964(02)00284-0

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.